{"@type": "dcat:Dataset", "accessLevel": "public", "bureauCode": ["009:25"], "contactPoint": {"@type": "vcard:Contact", "fn": "NIH", "hasEmail": "mailto:info@nih.gov"}, "description": "Purpose\n          The present study aimed at evaluating the efficacy of Raltitrexed, a specific thymidilate synthase inhibitor, in patients with advanced colorectal cancer (ACC) in relapse (>8 weeks) after a prior response or disease stabilization to first-line chemotherapy combination with lrinotecan+5-Fluorouracil (5-FU)+Leucovorin (LV).\n        \n        \n          Methods\n          Twenty-five patients with metastatic ACC entered; 17 males/8 females, median age 61 (range: 47\u201370), median Karnovsky PS: 80 (70\u201390), and sites of metastases; liver: 21, lung: 4, lymph nodes: 7, peritoneal: 5 and a life expectancy of at least 3 months, were entered in the present pilot study. All patients had progressed after prior chemotherapy with lrinotecan+5-FU+LV. Raltitrexed was administered at a dose of 3 mg/m2 i.v. every 21 days.\n        \n        \n          Results\n          Three patients (12%) achieved a partial response (PR), 8 (32%) had stable disease (SD), and the remaining 14 (56%) developed progressive disease (PD). Median time-to-progression (TTP) was 5.5 months (range, 2\u20138.5), and median overall survival (OS) 8 months (range, 4.0\u201312.5). Toxicity was generally mild; it consisted mainly of myelosuppression; neutropenia grade 1\u20132: 52%-grade 3: 28%, and anemia grade 1\u20132 only: 36%. Mild mucositis grade 1\u20132 occured in 13.5% of patients and was the principal non-hematologic toxicity.\n        \n        \n          Conclusion\n          Response to treatment with Raltitrexed is limited in patients with ACC failing after an initial response or non-progression to the weekly lrinotecan+5-FU+LV combination. However, it appears that a limited number of patients with PR/SD may derive clinical benefit, but final proof would require a randomized study.", "distribution": [{"@type": "dcat:Distribution", "description": "Visit the original government dataset for complete information, documentation, and data access.", "downloadURL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC65542/", "mediaType": "text/html", "title": "Official Government Data Source"}], "identifier": "https://healthdata.gov/api/views/qqyp-5tpm", "issued": "2025-07-14", "keyword": ["chemotherapy-response", "colorectal-cancer", "metastatic-cancer", "nih", "raltitrexed-treatment"], "landingPage": "https://healthdata.gov/d/qqyp-5tpm", "modified": "2025-09-06", "programCode": ["009:032"], "publisher": {"@type": "org:Organization", "name": "National Institutes of Health"}, "theme": ["NIH"], "title": "Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy"}